EGFR+ Lung Cancer

>

Latest News

FDA Clears Amivantamab/Chemotherapy Combo in EGFR-Mutant NSCLC
FDA Clears Amivantamab/Chemotherapy Combo in EGFR-Mutant NSCLC

September 20th 2024

The approval of amivantamab plus carboplatin and pemetrexed is supported by data from the phase 3 MARIPOSA-2 trial.

Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC
Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC

September 14th 2024

Dexamethasone Prophylaxis Reduces IRRs in Amivantamab Treatment
Dexamethasone Prophylaxis Reduces IRRs in Amivantamab Treatment

September 11th 2024

Amivantamab/Lazertinib Shows Potential in Atypical EGFR-Mutant Lung Cancer
Amivantamab/Lazertinib Shows Potential in Atypical EGFR-Mutant Lung Cancer

August 20th 2024

FDA Clears Lazertinib/Amivantamab for First-Line EGFR-Mutated NSCLC
FDA Clears Lazertinib/Amivantamab for First-Line EGFR-Mutated NSCLC

August 20th 2024

More News